TCBP logo

TC Biopharm (Holdings) (TCBP) Financials

Balance sheets

Jun 1, 2024Mar 1, 2024Jun 1, 2023Mar 1, 2023Dec 31, 2022Jun 30, 2022Dec 31, 2021Sep 30, 2021Dec 31, 2020

Total Assets

$8.7 M(-5.2%)$9.2 M(-11.7%)$10.4 M-$13.7 M(-17.0%)$16.5 M(+52.0%)$10.8 M(+13.0%)$9.6 M(-3.2%)$9.9 M

Current Assets

$5.0 M(-5.8%)$5.3 M(-15.0%)$6.2 M-$9.0 M(-24.3%)$11.9 M(+128.9%)$5.2 M(+39.8%)$3.7 M(+23.2%)$3.0 M

Non Current Assets

$3.7 M(-4.5%)$3.9 M(-6.6%)$4.1 M-$4.7 M(+2.2%)$4.6 M(-19.1%)$5.6 M(-4.0%)$5.9 M(-14.8%)$6.9 M

Total Liabilities

$6.2 M(-21.1%)$7.8 M(-0.5%)$7.8 M-$13.3 M(-12.9%)$15.2 M(-54.1%)$33.2 M(+24.8%)$26.6 M(+83.8%)$14.5 M

Current Liabilities

$4.5 M(-25.8%)$6.0 M(+4.6%)$5.8 M-$11.1 M(+4.8%)$10.6 M(-61.9%)$27.8 M(+36.3%)$20.4 M(+257.1%)$5.7 M

Long Term Liabilities

$1.7 M(-5.5%)$1.8 M(-14.5%)$2.1 M-$2.2 M(-53.2%)$4.6 M(-14.0%)$5.4 M(-12.9%)$6.2 M(-29.1%)$8.8 M

Shareholders Equity

$2.5 M(+85.8%)$1.4 M(-46.1%)$2.5 M-$400.9 K(-67.6%)$1.2 M(+105.5%)-$22.3 M(-31.5%)-$17.0 M(-272.6%)-$4.6 M

Book Value

$2.5 M(+85.8%)$1.4 M(-46.1%)$2.5 M-$400.9 K(-67.6%)$1.2 M(+105.5%)-$22.3 M(-31.5%)-$17.0 M(-272.6%)-$4.6 M

Working Capital

$536.1 K(+175.7%)-$708.0 K(-243.9%)$492.0 K--$2.1 M(-256.2%)$1.3 M(+105.9%)-$22.6 M(-35.5%)-$16.7 M(-520.4%)-$2.7 M

Cash And Cash Equivalents

$1.3 M(+2.6%)$1.2 M(-48.8%)$2.4 M-$5.8 M(-20.0%)$7.3 M(+244.0%)$2.1 M(+1.6%)$2.1 M(+104.3%)$1.0 M

Accounts Payable

$1.2 M(-51.0%)$2.4 M(+102.3%)$1.2 M-$1.1 M(-47.9%)$2.0 M(+6.7%)$1.9 M(+4.2%)$1.8 M(+111.8%)$870.0 K

Accounts Receivable

---------

Short Term Debt

$398.1 K(+2.3%)$389.0 K(-53.6%)$837.8 K-$1.2 M(-32.3%)$1.8 M(-82.8%)$10.2 M(+41.8%)$7.2 M(+1094.9%)$603.3 K

Long Term Debt

$1.7 M(-5.5%)$1.8 M(-14.5%)$2.1 M-$2.2 M(-8.7%)$2.4 M(-17.4%)$2.9 M(-5.0%)$3.0 M(-13.7%)$3.5 M

Total Debt

$2.1 M(-4.1%)$2.2 M(-25.7%)$2.9 M(+100.0%)$0.0(-100.0%)$3.4 M(-18.7%)$4.1 M(-68.4%)$13.1 M(+27.9%)$10.2 M(+148.5%)$4.1 M

Debt To Equity

0.8(-48.1%)1.6(+37.9%)1.2-8.4(+150.4%)3.4(+917.1%)-0.4(-5.1%)-0.4(-100.0%)0.0

Current Ratio

1.1(+27.3%)0.9(-19.3%)1.1-0.8(-28.3%)1.1(+494.7%)0.2(+5.6%)0.2(-66.0%)0.5

Quick Ratio

---------

Inventory

---------

Retained Earnings

-$55.8 M(-4.9%)-$53.2 M(-27.0%)-$41.9 M--$40.4 M(-3.7%)-$39.0 M(+13.8%)-$45.2 M(-13.8%)-$39.7 M(-46.5%)-$27.1 M

PB Ratio

2.1(-11.0%)2.4(-70.5%)8.0-167.1(+40.3%)119.1---

Income statements

Jun 1, 2024Mar 1, 2024Jun 1, 2023Mar 1, 2023Dec 31, 2022Jun 30, 2022Dec 31, 2021Sep 30, 2021Dec 31, 2020

EPS

-$5.1(+77.3%)-$22.3(-159.2%)$37.7(+162.5%)-$60.3---$2689.3(+45.7%)-$4956.3(-897.4%)-$496.9

TTM EPS

-$27.4(-278.2%)$15.4(+168.0%)-$22.6(+62.5%)-$60.3---$7645.5(-40.2%)-$5453.2(-997.4%)-$496.9

Revenue

------$666.8 K(-2.2%)$682.0 K(+4.5%)$652.7 K

TTM Revenue

------$1.3 M(+1.1%)$1.3 M(+104.5%)$652.7 K

Total Expenses

$2.6 M(-40.6%)$4.4 M(-3.0%)$4.5 M(-11.1%)$5.1 M--$3.8 M(+4.1%)$3.7 M(+31.3%)$2.8 M

Operating Expenses

$2.6 M(-40.6%)$4.4 M(-3.0%)$4.5 M(-11.1%)$5.1 M--$3.8 M(+4.1%)$3.7 M(+31.3%)$2.8 M

Cost Of Goods Sold

---------

TTM Cost Of Goods Sold

---------

Gross Profit

---------

TTM Gross Profit

---------

Gross Margin

---------

Operating Profit

-$2.6 M(+40.6%)-$4.4 M(+3.0%)-$4.5 M(+11.1%)-$5.1 M---$3.1 M(-5.5%)-$3.0 M(-39.5%)-$2.1 M

TTM Operating Profit

-$7.0 M(+21.5%)-$8.9 M(+7.3%)-$9.6 M(-88.9%)-$5.1 M---$6.1 M(-19.7%)-$5.1 M(-139.5%)-$2.1 M

Operating Margin

-------470.4%(-7.9%)-435.8%(-33.5%)-326.4%

Net Income

-$2.5 M(+40.5%)-$4.2 M(-439.0%)$1.2 M(+261.1%)-$771.7 K---$5.3 M(+45.7%)-$9.7 M(-456.0%)-$1.7 M

TTM Net Income

-$6.7 M(-126.2%)-$3.0 M(-730.6%)$471.1 K(+161.1%)-$771.7 K---$14.9 M(-30.7%)-$11.4 M(-556.0%)-$1.7 M

Net Margin

-------788.4%(+44.5%)-1420.7%(-432.1%)-267.0%

EBIT

-$2.6 M(+40.6%)-$4.4 M(+3.0%)-$4.5 M(+11.1%)-$5.1 M---$3.5 M(+58.7%)-$8.5 M(-298.1%)-$2.1 M

TTM EBIT

-$7.0 M(+21.5%)-$8.9 M(+7.3%)-$9.6 M(-88.9%)-$5.1 M---$12.0 M(-12.9%)-$10.6 M(-398.1%)-$2.1 M

EBITDA

-$2.4 M(+42.0%)-$4.2 M(+2.3%)-$4.3 M(+11.2%)-$4.8 M---$3.2 M(+61.1%)-$8.1 M(-358.1%)-$1.8 M

TTM EBITDA

-$6.6 M(+21.9%)-$8.5 M(+7.0%)-$9.1 M(-88.8%)-$4.8 M---$11.3 M(-14.0%)-$9.9 M(-458.1%)-$1.8 M

Selling, General & Administrative Expenses

$1.4 M(-48.2%)$2.7 M(+45.3%)$1.9 M(-31.1%)$2.7 M--$1.6 M(+9.8%)$1.4 M(+97.0%)$733.0 K

TTM SGA

$4.1 M(-10.1%)$4.6 M(+0.1%)$4.6 M(+69.0%)$2.7 M--$3.0 M(+39.2%)$2.2 M(+197.0%)$733.0 K

Depreciation And Amortization

$151.3 K(-6.1%)$161.1 K(-22.4%)$207.5 K(-5.7%)$220.0 K---$1.1 M-

TTM D&A

$312.4 K(-15.3%)$368.6 K(-13.8%)$427.5 K(+94.3%)$220.0 K---$1.1 M-

Interest Expense

------$2.6 M(+62.9%)$1.6 M(+1642.3%)$91.3 K

TTM Interest Expense

------$4.2 M(+148.6%)$1.7 M(+1742.3%)$91.3 K

Income Tax

-$133.5 K(+5.0%)-$140.5 K(+62.6%)-$375.5 K(+22.8%)-$486.2 K---$835.9 K(-120.5%)-$379.1 K(+20.7%)-$478.3 K

TTM Income Tax

-$274.0 K(+46.9%)-$516.0 K(+40.1%)-$861.7 K(-77.2%)-$486.2 K---$1.2 M(-41.7%)-$857.4 K(-79.3%)-$478.3 K

PE Ratio

-0.9-------

PS Ratio

---------

Cashflow statements

Jun 1, 2024Mar 1, 2024Jun 1, 2023Mar 1, 2023Dec 31, 2022Jun 30, 2022Dec 31, 2021Sep 30, 2021Dec 31, 2020

Cash From Operations

-$3.4 M(-12.3%)-$3.1 M(+39.3%)-$5.0 M(-42.3%)-$3.5 M----$4.2 M-

TTM CFO

-$6.5 M(+19.8%)-$8.1 M(+5.6%)-$8.6 M(-142.3%)-$3.5 M----$4.2 M-

Cash From Investing

-$37.9 K(-433.8%)-$7100.0(+92.5%)-$94.9 K(+46.2%)-$176.5 K----$125.7 K-

TTM CFI

-$45.0 K(+55.9%)-$102.0 K(+62.4%)-$271.4 K(-53.8%)-$176.5 K----$125.7 K-

Cash From Financing

$3.5 M(+196.7%)$1.2 M(+180.9%)$421.0 K(-91.2%)$4.8 M---$5.4 M-

TTM CFF

$4.7 M(+192.6%)$1.6 M(-69.3%)$5.2 M(+8.8%)$4.8 M---$5.4 M-

Free Cash Flow

-$3.5 M(-13.3%)-$3.1 M(+40.3%)-$5.1 M(-38.1%)-$3.7 M----$4.3 M-

TTM FCF

-$6.5 M(+20.3%)-$8.2 M(+7.4%)-$8.8 M(-138.1%)-$3.7 M----$4.3 M-

CAPEX

-------$125.7 K-

TTM CAPEX

-------$125.7 K-

Dividends Paid

---------

TTM Dividends Paid

---------

TTM Dividend Per Share

---------

TTM Dividend Yield

---------

Payout Ratio

---------